Effect of methylation modification on the expression of Cosmc gene in peripheral B lymphocyte of IgA nephropathy patients

Journal of Sichuan University (Medical Science)

Volumn 42, Issue 6, 2011, Pages 762-765

  Qin, Wei ^a   Zhong, Xiang ^a   Fan, Jun Ming ^a   Liu, Xian Rong ^a   Li, Zi ^a   Ma, Xing Yi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cosmc gene; De methylation modification; IgA nephropathy

Indexed keywords

EID: 82655171665     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol, 2005, 16(7):2088-2097. (Pubitemid 41716440)
2. Xu LX, Zhao MH. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int, 2005;68(1), 167-172.
3. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int, 2004, 65(5):1544-1547. (Pubitemid 38590997)
4. Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int, 2004;65(4):1135-1144. (Pubitemid 38406951)
5. Hennet T. The galactosyltransferase family. Cell Mol Life Sci, 2002;59(7):1081-1095.
6. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci USA, 2002:99(26):16613-16618. (Pubitemid 36034021)
7. Allen AC, Topham PS, Harper SJ, et al. Leucocyte beta 1, 3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant, 1997, 12(4), 701-706. (Pubitemid 27170423)
8. Qin W, Zhou Q, Yang LC, et al. Peripheral B lymphocyte betal, 3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med, 2005;258(5):467-477. (Pubitemid 41546563)
9. Felner KM, Dinter A, Cartron JP, et al. Repressed beta-1, 3-galactosyltransferase in the Tn syndrome. Biochim Biophys Acta, 1998;1406(1):115-25.
10. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 2001;29(9): e45.
11. Zhong X, Qin W, Fan JM. Sequence analysis of beta 1, 3- galactosyltranferase specific molecular chaperone Cosmc gene coding region in IgA nephropathy patients. CRTER, 2007, 11(21):4251-4254. (Pubitemid 47054370)
12. Ju T, Cummings RD. Protein glycosylation, chaperone mutation in Tn syndrome. Nature, 2005, 437(7063), 1252. (Pubitemid 41568663)
13. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem, 2002, 71, 635-700. (Pubitemid 34800232)
14. Serio KJ, Johns SC, Luo L, et al. Lipopolysaccharide downregulates leukotriene C4 synthase gene expression in a cellspecific manner in the monocyte-like cell line, THP-1. Chest, 2003;123(3 Suppl):426S. (Pubitemid 36315446)
15. Hashimoto S, Morohoshi K, Suzuki T, et al. Lipopolysaccharide-inducible gene expression profile in human monocytes. Scand J Infect Dis, 2003;35(9):619-627. (Pubitemid 37336883)
16. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood, 2007;110(7):2302- 2308. (Pubitemid 47523148)
17. Kaminskas E, Farrell A, Abraham S, et al. Approval summary, azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res, 2005, 11(10):3604-3608. (Pubitemid 40685574)